» Articles » PMID: 8137296

Amplification and Overexpression of Cyclin D1 in Breast Cancer Detected by Immunohistochemical Staining

Overview
Journal Cancer Res
Specialty Oncology
Date 1994 Apr 1
PMID 8137296
Citations 212
Authors
Affiliations
Soon will be listed here.
Abstract

Immunohistochemical staining with a monoclonal antibody against human cyclin D1 can be used to identify breast cancers that have an amplification of the q13 region of chromosome 11. In general, the intensity of staining is directly proportional to the degree of DNA amplification. In two unusual tumors, in which the CCND1 locus is highly amplified but staining is relatively weak, it appears that the DNA has undergone rearrangement and that the amplified/rearranged CCND1 allele may have reduced transcriptional activity. More significantly, the immunohistochemical technique identifies additional tumors in which the cyclin D1 gene is overexpressed with only marginal or undetectable increases in copy number, implying that other mechanisms can lead to deregulated expression. These results suggest that the frequency of overexpression is much higher than previously concluded from DNA-based analyses and that more than one-third of human breast cancers may contain excessive levels of cyclin D1. The technique we describe should facilitate the detection of this abnormality in a clinical setting and clarify its prognostic significance.

Citing Articles

Expression of Cyclin D1 and Claudin-1 in Invasive Breast Carcinoma and Their Correlation with Clinicopathological Parameters.

Sehrawat R, Dhawan V, Roy M, Kediya A, Nijhawan V Iran J Pathol. 2025; 19(4):408-414.

PMID: 40034931 PMC: 11872039. DOI: 10.30699/ijp.2024.2028643.3299.


Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer.

Asciolla J, Wu X, Adamopoulos C, Gavathiotis E, Poulikakos P Nat Cancer. 2025; 6(1):24-40.

PMID: 39885369 DOI: 10.1038/s43018-024-00893-z.


BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair.

Chi S, Wei F, Li Y, Yu L, Ma C, Fang Y Transl Oncol. 2024; 51:102212.

PMID: 39591896 PMC: 11629338. DOI: 10.1016/j.tranon.2024.102212.


Intramammary Labeling of Epithelial Cell Division.

Machiela M, Hovey R J Mammary Gland Biol Neoplasia. 2024; 29(1):17.

PMID: 39412532 PMC: 11485144. DOI: 10.1007/s10911-024-09570-4.


Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer.

Poulet S, Dai M, Wang N, Yan G, Boudreault J, Daliah G Mol Cancer. 2024; 23(1):118.

PMID: 38831405 PMC: 11145857. DOI: 10.1186/s12943-024-02029-4.